Tampa Bay Heart Institute

Sarah Cannon Research Partner

Research Partner with SCRI

In June 2011, The Tampa Bay Heart Institute at Northside Hospital partnered with Sarah Cannon Research Institute (SCRI), one of the largest global clinical research programs. This partnership designates TBHI as a cardiovascular clinical research strategic site.

SCRI’s rapidly expanding cardiovascular research network enables hospitals and physician practices to develop their research programs and provides the opportunity for patients to consider participation in clinical trials in their own community.

The benefits of this relationship are far-reaching for Northside patients and their families. Together, we will now be able to provide patients with:

  • Expanded treatment options -- improved local access to clinical trials and leading-edge treatments that can be administered close to home;
  • Consistent care -- an increased ability to retain continuity of care with physicians they know and trust; and
  • Innovative medicine -- the ability to participate in investigator-initiated trials with promising drug combination therapies.

As part of the agreement, SCRI will help manage industry sponsored and investigator initiated clinical trials in interventional cardiology and electrophysiology.  In addition, the staff will have access to SCRI’s physician experts and clinical research team.

Current Research Trials at Northside Hospital:

ION: Eluting Platinum Chromium Coronary Stent System US Post-Approval StudyPrincipal Investigator:  Dr Andrew Rosenthal, Sub-Investigator:  Dr Minor, Dr Walsh, Dr MukayedSponsor: Boston ScientificStatus:  Closed to enrollment, 39 patients enrolled at this site and currently in follow up (5 years)

CABANA: Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation TrialPrincipal Investigator:  Dr Robert Sheppard, Sub-Investigator:  Dr CardonaSponsor:  National Heart Lung and Blood Institute, Investigator Initiated Trial Mayo Clinic, Dr Douglas Packer, study management DCRIStatus:  Open to enrollment.

QuadPas: Quadripolar Pacing Post Approval Study – Quadra CRT-D and Quartet LV Lead (10 programmable vectors)Principal Investigator:  Dr Robert Sheppard, Sub-Investigator:  Dr Francisco CardonaSponsor: St Jude MedicalStatus: Open to enrollment, currently 11 patients enrolled.

SAVI-PCI: Efficacy of Tirofiban High-Dose Bolus plus shortened Infusion duration vs. Label-dosing Eptifibatide in patients undergoing PCIPrincipal Investigator:  Dr Andrew Rosenthal, Sub-Investigator: Dr Walsh, Dr Mukayed Sponsor: Medicure Inc.Status:Open to enrollment.

Upcoming Research Trials at Northside Hospital:

ABLATE Post-Approval Study – Atricure Synergy Ablation lesions for non-paroxysmal forms of atrial fibrillation treatment during concomitant on-pump endo-epicardial cardiac surgery.

Principal Investigator:  Dr Michael DeFrain, Sub-Investigator Dr Bryan

Sponsor: Atricure 

REVEAL – Medtronic – prospective, single-arm, open-label, multi-center postmarket interventional clinical study to determine, via continuous monitoring with the REVEAL XT implantable cardiac monitor, the incidence of atrial fibrillation in patients suspected to be at high risk for having AF.

Principal Investigator:  Dr Peter Wassmer, Sub-Investigators Dr Francisco Cardona, Dr Robert Sheppard, Dr Dennis Cassidy.

Status: open to enrollment, 1 patient enrolled.

GLORIA –  Sponsor: Boehringer-Ingelheim

Principal Investigator:  Dr Francisco Cardona, Sub-Investigator Dr Robert Sheppard

REGULATE – Sponsor Regado Inc., study managed by Duke Clinical Research Institute

A randomized, open-label, multi-center, active-controlled, parallel group study to determine the efficacy and safety of the REG1 anticoagulation system compared to bivalirudin in patients undergoing percutaneous coronary intervention.

Principal Investigator:  Dr Andrew Rosenthal, Sub-Investigators Dr John Walsh, Dr Usama Mukayed.

Protocol CRLX030A2301 Novartis

A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients.

Principal Investigator:  Dr Robert Sanchez, Sub-Investigator Melinda Coffman, plus others.

For more information about the Tampa Bay Heart Institute, please contact us at:

1-888-598-9586

Our patients have access to an experienced team of physicians, nurses, clinicians and rehabilitation specialists.
Find a Doctor